NCT01014351 - Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

August 31, 2013

Conditions

Metastatic Melanoma

Interventions

DRUG

Paclitaxel

Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle

DRUG

Carboplatin

Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle

DRUG

Everolimus

Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle

Trial Locations (12)

Center for Cancer and Blood Disorders, Bethesda

Peninsula Cancer Institute, Newport News

Northeast Georgia Medical Center, Gainesville

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Oncology Hematology Care, Cincinnati

Oncology Hematology of SW Indiana, Evansville

Grand Rapids Oncology Program, Grand Rapids

Research Medical Center, Kansas City

Nebraska Methodist Cancer Center, Omaha

Hematology Oncology Clinic, LLP, Baton Rouge